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Introduction
Osteoarthritis (OA) remains the major disease causing 
joint degeneration and disability worldwide (Cross et al. 
2014). OA is a strongly age-related disorder; however, it 
can affect young to middle-aged individuals or athletes 
and have a significant impact on people’s lives. Common 
symptoms of OA include: focal dysregulation within the 
joint, stiffness, synovial membrane swelling and pain 
(Goldring and Goldring 2007). The pathogenesis of OA is 
partly caused by the imbalance between cartilage extracel-
lular matrix (ECM) synthesis and degradation (Goldring 
and Goldring 2010). The excessive mechanical joint stim-
ulation is one of the main risk factors promoting cartilage 
surface thinning, erosion and loss of its elastic properties 
(Ko et al. 2013). The abnormal mechanical stress can lead 
to chondrocyte differentiation and production of cytokines, 
aggrecanases and matrix metalloproteinases (MMPs) 
which disrupt cartilage ECM (Loeser et al. 2012). Carti-
lage surface wear and chondrocyte apoptosis are often 
accompanied by subchondral bone adaptive modelling (Li 
et al. 2013) and synovitis (Rahmati et al. 2016). Presence 
of joint space narrowing, osteophytes, subchondral bone 
abnormalities or accumulation of the synovial fluid are 
the clinical features of OA (Bay-Jensen et al. 2010). The 
diagnosis of OA is usually confirmed by X-ray, magnetic 
resonance imaging or arthroscopy. Yet, these structural 
changes mostly detect late stages of the disease, and too 
Abstract Transglutaminase 2 (TG2) is highly expressed 
during chondrocyte maturation and contributes to the for-
mation of a mineralised scaffold by introducing crosslinks 
between extracellular matrix (ECM) proteins. In healthy 
cartilage, TG2 stabilises integrity of ECM and likely 
influences cartilage stiffness and mechanistic properties. 
At the same time, the abnormal accumulation of TG2 in 
the ECM promotes chondrocyte hypertrophy and carti-
lage calcification, which might be an important aspect of 
osteoarthritis (OA) initiation. Although excessive joint 
loading and injuries are one of the main causes leading 
to OA development, it is now being recognised that the 
presence of inflammatory mediators accelerates OA pro-
gression. Inflammatory signalling is known to stimulate 
the extracellular TG2 activity in cartilage and promote 
TG2-catalysed crosslinking of molecules that promote 
chondrocyte osteoarthritic differentiation. It is, however, 
unclear whether TG2 activity aims to resolve or aggravate 
damages within the arthritic joint. Better understanding 
of the complex signalling pathways linking inflamma-
tion with TG2 activities is needed to identify the role of 
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little is known about the early mechanism underlying joint 
degeneration in OA.
Transglutaminase 2 (TG2) is an interesting target 
involved in OA pathogenesis as accumulation of TG2 in 
the ECM promotes chondrocyte hypertrophy and cartilage 
calcification (Tarantino et al. 2011), which mechanism 
might be linked to early events of the disease. TG2 belongs 
to the family of transglutaminases (TG), the enzymes that 
catalyse Ca2+-dependent acyl-transferase reactions (Eck-
ert et al. 2014). Depending on the nature of the substrates 
available, TG mediate protein crosslinking or small amine 
incorporation through reaction of transamidation; pep-
tide esterification; or catalyse hydrolysis by deamidation 
or isopeptide cleavage. The most characteristic reaction 
mediated by TG2 is that of crosslinking, which results in 
the formation of covalent Nε(γ-glutamyl)lysyl isopeptide 
bonds between proteins or within polypeptides (Lorand 
and Graham 2003). In humans, there are nine TG family 
members described (Eckert et al. 2014), but the main TG 
activity in skeletal tissues comes from the activity of TG2 
and FXIIIA (Thomázy and Davies 1999; Rosenthal et al. 
2001; Deasey et al. 2013). TG1 and TG3 are also detected 
in the skeletal tissues (Deasey et al. 2013); however, the 
specific biological functions of TG1 and TG3 in muscu-
loskeletal system remain largely unknown, and this awaits 
further investigation. In many instances, TG2 is expressed 
at much higher level than any of the other enzymes of the 
family, thus can display various functions in disease pro-
cesses (Iismaa et al. 2009). The predominant role of TG2 
is in cell stress response and tissue repair, regulating hall-
mark events such as ECM remodelling and cell activation 
(Stephens et al. 2004). Yet, aberrant TG2 activity may 
also promote formation of protein modifications that can 
lead to tissue fibrosis (Verderio et al. 2004; Collighan and 
Griffin 2009). TG2 also drives the destructive immune 
responses associated with coeliac disease (Sollid and Jabri 
2011) and with rheumatoid arthritis (Dzhambazov et al. 
2009; Lauzier et al. 2012). Upregulation of TG2 in both 
OA patient samples as well as in OA animal models has 
been well established but the main function of TG2 in OA 
pathogenesis remains enigmatic. Sufficient knowledge of 
TG2 functions at the initial stages of OA development is 
needed to understand whether TG2 role is to rescue car-
tilage damage or promote the irreversible changes within 
the joint.
Inflammatory signalling stimulates TG2 extracellular 
crosslinking activities in articular cartilage (Johnson et al. 
2001). This is important as the detection of inflammatory 
molecules in the OA joint in recent years has shed new 
light for more research into that area (de Lange-Brokaar 
et al. 2012; Rahmati et al. 2016). Various proinflammatory 
mediators were found to be elevated in the osteoarthritic 
joints leading to cartilage destruction, such as interleukins 
(IL-1β and IL-6), tumour necrosis factor α (TNFα), matrix 
metalloproteinases (MMP 1,3,9 and 13) and aggrecanases 
(ADAMTS-4 and ADAMTS-5) (Loeser et al. 2012). Tissue 
markers released by infiltrating macrophages or synovio-
cytes such as advanced glycation endproducts, high-mobil-
ity group box chromosomal protein 1 (Kyostio-Moore et al. 
2011), components of the complement system (C3a and 
C5b-9) (Wang et al. 2012a) are indicative of “microinflam-
mation” taking place in OA joint (Goldring and Berenbaum 
2015). Thus, recent evidence suggests that OA should not 
be considered solely as a degenerative condition as both 
local inflammation and low-level systemic inflammation 
play a role in disease progression (Berenbaum 2012; de 
Lange-Brokaar et al. 2012). The presence of a novel link 
between TG2 and innate immunity suggests that fast accu-
mulation of extracellular TG2 (Adamczyk et al. 2015) 
might occur e.g., during joint injury. This review will sum-
marise the most recent findings about the functions of TG2 
in healthy and arthritic cartilage, to highlight an important 
role of TG2 as a potential therapeutic target.
TG2 expression and activity during chondrocyte 
maturation
TG2 is expressed and becomes activated at the early 
stages of long bone development (Aeschlimann and 
Thomazy 2000). The vast accumulation of TG2 in the 
cytosol of pre-hypertrophic chondrocytes is followed 
by TG2 secretion and catalytic activity, which is later 
detected in the ECM (Aeschlimann et al. 1995). The 
expression of TG2 diminishes when chondrocytes reach 
the hypertrophic stage (Aeschlimann et al. 1993). Inter-
estingly, externalisation of TG2 from maturing chon-
drocytes precedes mineralisation of newly formed ECM 
(Aeschlimann et al. 1995). It is likely that the retinoids 
have a significant role in regulating TG2 expression 
during ossification through binding to RAR and RXR 
enhancer elements upstream of the TGM2 gene (Nagy 
et al. 1997). TG-catalysed crosslinks stabilise structure 
of bone and hyaline cartilage matrix, therefore the pres-
ence of enzymatically active TG2 is considered to be an 
important step in long bone development (Aeschlimann 
et al. 1995). TG2 might also act as an autocrine factor and 
control glycosaminoglycans (GAGs) synthesis by regulat-
ing the xylosyltransferase 2 transcription during chondro-
cyte development (Nurminsky et al. 2011). In the pellet 
cultures of chicken mesenchymal stem cells, the upregu-
lation of TG2 accelerates the transition of chondrocytes 
into the pre-hypertrophic stage and decreases deposition 
of extracellular matrix rich in GAGs (Nurminsky et al. 
2011). Thus, TG2 plays a role in controlling matrix depo-
sition and crosslinking chondrocyte ECM.
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TG2 protein upregulation does not always correlate 
with an increase in TG2 catalytic activity. For example, 
TG2 activity is initially detected in the cartilage anlagen 
of the spine at E12.5 stage of mouse embryonic develop-
ment, followed by the increase in the perichondrium (Itoh 
et al. 2013), which then slowly diminishes despite the TG2 
protein expression remaining high. It is possible that the 
hypoxic environment of cartilage modulates TG2 levels 
throughout development, as hypoxia is a strong inducer 
of TG2 expression e.g., in cancer cells (Kumar and Mehta 
2012). Clearly, more investigation is needed to underline 
the mechanisms controlling TG2 expression and activity 
during development of hyaline, elastic and fibrocartilage.
Regulation of TG2 activity and release 
in chondrocytes
TG2 enzymatic activity is allosterically regulated by gua-
nine nucleotides (GTP/GDP) and Ca2+ ions (Achyuthan and 
Greenberg 1987; Begg et al. 2006). Current understanding 
suggests that TG2 is rapidly converted from “closed” into 
the “open” conformation by high extracellular Ca2+ con-
centrations (Pinkas et al. 2007). On the other hand, GTP/
GDP association promotes transition into more compact 
conformation (Pinkas et al. 2007). GTP is highly impor-
tant as molecular manipulation of GTP-binding residues 
inhibits TG2 externalisation from human chondrocytes 
(Johnson and Terkeltaub 2005). TG2 can act as an ATPase, 
however, the affinity for ATP is several orders of magnitude 
lower compared to GTP (Achyuthan and Greenberg 1987; 
Schaertl et al. 2010). Hydrolysis of extracellular ATP by 
TG2 was postulated to be a major function of cell-surface 
TG2 in osteoblasts, and the hydrolysis product inorganic 
pyrophosphate is likely involved in promoting mineralisa-
tion (Nakano et al. 2007). Recently, it was shown that chon-
drocytes secrete articular cartilage matrix vesicles contain-
ing mRNA for TG2 and FXIIIA, together with ANK, type II 
collagen, GAPDH and aggrecan (Mitton et al. 2009). Better 
understanding of TG2 externalisation from chondrocytes 
would tell us more about its localisation and enzymatic 
activity in the specific domains of cartilage ECM.
TG2–ECM interactions in articular cartilage
Chondrocyte cell surface and cartilage ECM is rich in 
potential binding partners for TG2. These include fibronec-
tin (FN), collagens of type II, III, V and XI, osteopon-
tin, osteonectin, fibrillin, laminin, syndecan-4, integrins, 
MMP-2 and many others (Lorand and Graham 2003; Bel-
kin 2011). Some of the similar substrates can be targeted 
by another transglutaminase, FXIIIA (Muszbek et al. 
2011). However, it was shown that TG2 and FXIIIA dis-
play a preference for distinct sites within the same molecu-
lar targets (Watanabe et al. 2013). In many instances, the 
interactions are independent of TG2 transamidation activ-
ity. For instance, TG2 binds FN at the I6II1,2I7-9 modules 
localised in the gelatin-binding region of FN, and this 
interaction restricts neither TG2 activity nor the interaction 
of FN with integrins (Gaudry et al. 1999). TG2 was also 
shown to associate with heparan sulphate chains of synde-
can-4, without causing changes in TG2 conformation and/
or affecting TG2/FN interactions (Scarpellini et al. 2009). 
TG2 interaction with syndecan-4 leads to protein kinase 
C-α activation (Telci et al. 2008) and results in inside-out 
signalling through β1 integrin. Although little is known 
about interaction of TG2 with type II collagen, it is likely 
that transamidation of TG2 affects the alignment of col-
lagen fibrils and their shape as shown for corneal stroma 
(Wang et al. 2014). This interaction might be potentially 
important in mediating mechanistic properties and shear 
stiffness of articular cartilage.
It is likely that proteoglycans influence TG2 localisa-
tion and activity in cartilage ECM. In other connective tis-
sues, one of the best studied examples is TG2 interaction 
with heparan sulphate chains on syndecan-4. Wang et al. 
(2012b) proposed a model, in which TG2-bound to synde-
can-4 in its “closed” form is shed from the cell surface by 
MMPs, which leads to TG2 “opening” and re-gaining of its 
enzymatic activity (Wang et al. 2012b). It is, however, not 
known if this mechanism might be accelerated during car-
tilage degradation in OA. Another group identified clusters 
of positively charged residues on the heparan sulphate that 
are accessible for TG2 binding in its compact or “closed” 
conformation (Lortat-Jacob et al. 2012). The release of TG2 
from this complex is achieved by an increase in Ca2+ ions, 
which reduces TG2 affinity for heparan sulphate (Lortat-
Jacob et al. 2012), suggesting that this binding might be 
compromised during tissue calcification. The in vivo data 
showing attenuation of TG2 extracellular activity in synde-
can-4−/− mice indicate that excessive TG2 externalisation 
could be abolished by specifically cleaving heparan sulphate 
chains of syndecan-4 (Scarpellini et al. 2014). Thus, reduc-
tion in syndecan-4 expression might have an affect on TG2 
levels in cartilage ECM due to lack of TG2 “trapping” by the 
heparan sulphate chains. Recently, syndecan-4 was shown 
to be regulating activity of ADAMTS-5 (Echtermeyer et al. 
2009), which is one of the primary aggrecanases driving car-
tilage proteolysis in OA models (Glasson et al. 2005). There-
fore, TG2 and syndecan-4 binding might reduce or promote 
ADAMTS-5 transactivation linked with cartilage destruction 
in OA. Conclusively, investigating TG2 and proteoglycan 
relationship in cartilage is an interesting avenue for future 
studies as these interactions might be important in mediating 
cartilage ECM fragmentation in inflammatory OA.
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Lessons from TG2−/− animals
Despite the important role of TG2 in cartilage and bone 
development, TG2−/− mice have no developmental abnor-
malities (De Laurenzi and Melino 2001; Nanda et al. 2001). 
The lack of obvious defects in TG2-deficient mice may be 
explained by the activity of other TGs (mainly FXIIIA) that 
partially compensate the absence of TG2 (see Table 1) (Dea-
sey et al. 2013). Many studies have been conducted with use 
of TG2−/− mice, and, collectively, these show that deficien-
cies become apparent once the mice are subjected to different 
types of insults (Oh et al. 2011). The inflammatory response 
in TG2−/− mice is substantially different. This is manifested 
by an increase in IL-1β release and higher neutrophil accu-
mulation in response to monosodium urate crystals (MSU) 
crystal injection (Yen et al. 2015). Also slower clearance of 
apoptotic neutrophils is linked to reduced ability of mac-
rophage to effectively phagocytose cell debris (Rose et al. 
2006). Similarly, there is a significant increase in number of 
apoptotic cells in thymus of TG2−/− mice treated with dexa-
methasone and accelerated cell death of TG2−/− thymocytes 
exposed to apoptotic signalling (Nanda et al. 2001). This 
indicates that crosslinking of cellular content by TG2 might 
become important in controlling cell viability and apoptotic 
cell clearance especially in early inflammatory processes.
TG2 upregulation in OA cartilage
In the healthy knee joint, TG2 is mainly expressed in the 
superficial and deep zone of cartilage, as well as in the 
chondrocytic part of the menisci (Johnson et al. 2001). In 
the Hartley guinea pig model that spontaneously develops 
OA, TG2 expression in cartilage changes during disease 
progression (Huebner et al. 2009). Initially, TG2 is mainly 
upregulated in ECM of superficial and middle zone of car-
tilage, but with OA progression, it strongly accumulates 
in the surface layer. The enhanced formation of TG2-cata-
lysed Nε(γ-glutamyl)lysyl isopeptide bonds is also evident 
in OA tissue (Huebner et al. 2009). Likewise, strong TG2 
expression surrounding enlarged chondrocytes is detectable 
in cartilage collected from patients with severe OA (John-
son et al. 2001). There is a visible association between TG2 
increased activity when cartilage is fibrillated and eroded 
(Johnson et al. 2001).
TG2 levels and OA severity
Experiments with surgical induction of joint instability 
revealed that cartilage degradation is significantly reduced 
in TG2−/− mice, and this might be important for assess-
ing OA severity (Orlandi et al. 2009). At the same time, 
there is more osteophyte formation in the operated knee of 
TG2−/− mice; therefore, lack of TG2 does not completely 
abolish OA-associated changes within the subchondral 
bone region (Orlandi et al. 2009). This may relate to differ-
ences in the inflammatory response between wild-type and 
TG2−/− mice or be caused by higher FXIIIA activity in the 
lack of TG2. Human studies showed that increase in TG2 
levels in the synovial fluid from OA patients correlate with 
the histological score of disease severity (Huebner et al. 
2009). The same study also revealed that there is a positive 
correlation between increase in TG2 transamidation activ-
ity and meniscal degradation in OA patients above 60 years 
old. Remarkably, the mononuclear cells present in synovial 
fluid were suggested to be the source of TG2 in OA patient 
samples (Yen et al. 2015). Collective evidence suggests that 
Table 1  Compensation of TG2 expression and activity in TG2−/− 
mice based on the original data shown by (Deasey et al. 2013). In 
this study, the detailed analysis of hypertrophic cartilage (knee joint), 
non-hypertrophic cartilage (sternum) and skeletal muscle (limb, 
aorta, heart, kidney and liver) was performed to compare the TG 
gene expression and transamidation activity between wild-type and 
TG2−/− mice
This table was prepared based on the original data published by Deasey et al. (2013)
L low expressed, NC not changed, U upregulated, D downregulated, ND not detected
Wild-type mice TG2−/− mice Compensation




60 % FXIIIA (NC)
TG1 (U)
TG3 (U)






100 % FXIIIA (NC)
TG1 (D)
TG3 (ND)




60 % FXIIIA (D)
TG1 (NC)
40 % Lack
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synovial or cell-associated TG2 may be a potentially useful 
marker of disease progression.
Inside‑out and outside‑in signalling mediated 
by TG2 in OA
TG2 is involved in the pathologic cartilage calcification 
through inside-out and outside-in signalling (Fig. 1). Min-
eralisation of cartilage is mediated by hypertrophic chon-
drocytes, which fuse and enlarge during OA progression 
(Goldring 2000). Treatment of chondrocytes with all-trans 
retinoic acid (ATRA) stimulates TG2 expression and poten-
tiates chondrocyte re-differentiation from resting state into 
hypertrophic or “OA-like” chondrocytes (Johnson et al. 
2001). Alongside TG2 induction, ATRA promotes expres-
sion of hypertrophic markers such as alkaline phosphatase 
(AP), collagen type X, or metalloproteinase-13 (MMP-13) 
suggestive of a direct link (Johnson et al. 2003; Huebner 
et al. 2009). Interestingly, transient TG2 transfection is suf-
ficient to induce matrix calcification and collagen type X 
upregulation in human chondrocytes (Johnson and Terkel-
taub 2005) (Fig. 1a). In meniscal chondrocytes, the activ-
ity of both TG2 and nucleoside triphosphate pyrophos-
phohydrolase gradually increases with age (Johnson et al. 
2001). During spontaneous OA development in guinea 
pig, increased TG2 activity positively correlates with 
the increase of inorganic pyrophosphate and nucleotide 
pyrophosphatase phosphodiesterase (Johnson et al. 2004). 
Several studies demonstrated that FXIIIA transamidation 
activity stimulates mineralisation of osteoblast cultures 
(Al-Jallad et al. 2006; Nakano et al. 2010). Likely similar 
mechanism might be conserved in chondrocytes, whereby 
increase in TG2 transamidation is involved in pathological 
cartilage ECM calcification.
The in vitro experiments indicate that soluble TG2 
(sTG2) can also act as extracellular alarmin, promoting 
chondrocyte osteoarthritic differentiation through outside-
in signalling (Fig. 1b). Addition of sTG2 to the growth 
medium of human chondrocytes is sufficient to induce β1 
integrin signalling that causes phosphorylation of Rac1 and 
p38 kinase and, ultimately, type X collagen upregulation 
(Johnson and Terkeltaub 2005). Moreover, the presence 
of soluble and enzymatically active TG2 inhibits protein 
kinase A (PKA) signalling and, ultimately, cyclic adeno-
sine monophosphate (cAMP) production in chondrocytes, 
also causing matrix calcification (Nurminsky et al. 2011). 
Interestingly, the stimulation of bovine cartilage explants 
with sTG2 induces stronger type X collagen expression 
when TG2 was in complex with Mg-GTP (Johnson and 
Terkeltaub 2005). Thus, Johnson and Terkeltaub (2005) 
proposed an interesting hypothesis suggesting that patho-
logical changes in OA may, at least in part, be due to the 
presence of an inactive, Mg-GTP-bound form of TG2. In 
agreement with those findings, stimulation of human chon-
drocytes with GTP complexed TG2, increases MMP-13 
and type X collagen on mRNA levels (Tanaka et al. 2007). 
The rise in hypertrophic markers associates with elevated 
Fig. 1  Summary of TG2-driven “inside-out” (a) and “outside-in” (b) signalling linked with chondrocyte osteoarthritic differentiation
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AP activity and possibly occurs via α5β1 integrin signal-
ling and Fak phosphorylation. Hence, TG2, particularly in 
its compact conformation, might be involved in promoting 
hypertrophic changes and ECM calcification in cartilage.
Once released from the cells, TG2 becomes catalytically 
active in the extracellular space and catalyses reactions that 
might promote or contribute to the pathology of OA. TG2-
mediated crosslinking of the S100A11 molecule allow-
ing formation of  γ-glutamyl-ε-lysine isopeptide bridges 
turns it into a functional homodimer, which binds more 
efficiently to the cell surface receptor for advanced glyca-
tion end products (RAGE) (Cecil and Terkeltaub 2008). 
This enhances outside-in signalling, the activation of p38 
MAPK kinase and NFκB signalling pathways, and ulti-
mately induces chondrocyte hypertrophy.
Regulation of TG2 by anabolic and catabolic 
signalling
The anabolic signalling mediated by transforming growth 
factor β1 (TGF-β1) is an important mechanism control-
ling TG2 levels in cartilage and bone. TGF-β1 seems to 
be a slightly better inducer of TG2 protein expression than 
IL-1β but has no effect on elevating TG2 activity (John-
son et al. 2001). TG2 has been proposed to have a role in 
TGF-β1 activation (Szondy et al. 2003), and an increased 
expression of TGF-β1 in TG2−/− mice was reported (Tar-
antino et al. 2009). Therefore, TG2 in conjunction with 
TGF-β1 might be involved in ameliorating the inflamma-
tory responses in the resolution phase.
The catabolic responses mediated by chemokine CXCL1 
and CXCL8 (IL-8) are implicated in promoting aberrant 
TG2 activity (Merz et al. 2003). Also, treatment with proin-
flammatory IL-1β causes secretion of TG2 in mouse articu-
lar chondrocytes or bovine cartilage explants (Johnson et al. 
2003; Cecil and Terkeltaub 2008). Similarly, patient-derived 
meniscal cells effectively upregulate TG2 activity in the 
presence of IL-1β (Johnson et al. 2001). It is likely that nitric 
oxide (NO) released upon IL-1β priming is responsible for 
promoting TG2 expression as peroxynitrite donors signifi-
cantly enhance TG2 activity in a similar manner. TG2 seems 
to be the predominant TG responding to early catabolic sig-
nalling as IL-1β stimulation fails to induce transamidation 
activity of FXIIIA in cartilage (Johnson et al. 2003).
Role of TG2 in gout and rheumatoid arthritis
Although the aetiology of OA is different than gout or 
rheumatoid arthritis, some of the mechanisms regulating 
TG2 might be common and exist in inflammatory type 
of OA. Gout is a chronic inflammatory arthritis that is 
characterised by the deposition of monosodium urate crys-
tals (MSU) usually within the metatarsophalangeal, mid-
foot and ankle joints (Dalbeth et al. 2016). The TG2 mRNA 
levels are clearly enhanced in the synovial fluid collected 
from gouty but not from rheumatoid arthritis patients (Yen 
et al. 2015). Stimulation of cells with MSU crystals alone 
causes an enhanced TG2 mRNA expression in primary 
peripheral blood monocytes or macrophages (Yen et al. 
2015). It is likely that TG2 activity reduces the release of 
proinflammatory IL-1β and TNFα upon MSU exposure by 
enhancing production of anti-inflammatory TGF-β1 (Yen 
et al. 2015). Yet another study suggested that TG2 transam-
idation activity is not necessary to increase macrophage 
phagocytosis by TGF-β1 but be rather regulated by TG2 
binding to the nucleotides, particularly GDP, ATP or ADP 
(Rose et al. 2006).
Interesting evidence was reported about the role of TG2 
activity in rheumatoid arthritis (RA). RA is a chronic, auto-
immune disease, in which synovial inflammation drives 
destruction of cartilage and bone by activated blood cells 
infiltrating joint space (Pratt et al. 2009). Induction of 
experimental arthritis by type II collagen immunization 
increases TG2 activity in the areas of cartilage erosion and 
within inflammed synovial membrane (Lauzier et al. 2012). 
The arthritic fibroblast-like synoviocytes were shown to 
release enzymatically active TG2 at the sites of collagen 
type II degradation. Importantly, TG2 was suggested to be 
actively involved in development of autoimmunity due to 
its ability to modify an immunodominant fragment of type 
II collagen (CII260-270) (Dzhambazov et al. 2009). TG2 
crosslinking and/or deamidation of this epitope mediates a 
T-cell response to the CII260-270 fragment (Dzhambazov 
et al. 2009). Thus, TGs activity in RA animal models can 
enhance joint destruction by worsening the severity and 
histopathological features of the disease.
Conclusions
This review demonstrates that TG2 is an interesting target in 
inflammatory OA pathogenesis, as there is strong evidence 
both from human and animal models for the involvement of 
TG2 in OA progression. The literature suggests that aberrant 
TG2 upregulation in the arthritic joint might be aggravat-
ing OA severity by promoting tissue mineralisation, accel-
erating chondrocyte hypertrophy and potentially enhancing 
OA-linked signalling. Likewise, recent findings indicate that 
FXIIIA might be an important player in inflammatory arthri-
tis, as FXIIIA−/− mice are protected from cartilage and bone 
destruction, which might be due to reduced osteoclasts fusion 
and activity (Raghu et al. 2015). Interestingly, treatment of 
arthritic joints with inhibitor cystamine to block FXIIIA 
activity significantly ameliorated type II collagen-induced 
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arthritis severity in mice (Raghu et al. 2015). TG2 could also 
be involved as cystamine displays high specificity towards 
inhibiting TG2 transamination activity (Siegel and Khosla 
2007). Future studies should, therefore, address TG2 func-
tions within inflamed OA joint, taking into account the role 
of synovial membrane and subchondral bone into considera-
tion despite evidence suggesting TG2 mainly as an appropri-
ate marker of hypertrophic chondrocytes but not upregulated 
in the remodelled trabecular bone of OA patients (Tarquini 
et al. 2016). Recent findings demonstrating the role of P2X7 
receptor-dependent pore formation in TG2 externalisation 
(Adamczyk et al. 2015) might be relevant in the context of 
TG2 secretion from activated synovial macrophages. This 
would suggest the presence of a link between innate immu-
nity and TG2 externalisation, especially vital as P2X7 recep-
tor activation drives the inflammatory responses in joint dis-
eases (Labasi et al. 2002; Lopez-Castejon et al. 2010).
Managing and treating musculoskeletal diseases is a big 
challenge for ageing population, and there are currently no 
reliable biochemical markers for early patient diagnosis 
(Mobasheri et al. 2015). Evidence suggests that diagnostic 
assays based on the detection of proteins or peptides with 
post-translational modifications may have a higher speci-
ficity than assays detecting only changes in protein levels 
(Doyle and Mamula 2005). TG2 released by chondrocytes 
in OA could contribute to the elevated levels of γ-glutamyl-
ε-lysine crosslinks present in OA tissue. In summary, more 
research is needed to clarify if specific post-translational 
modifications are generated by TG2 in certain OA pheno-
types that could serve as biological indicators of the disease.
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